Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SH-SY5Y cells

Neuroscience Letters

Volumn 450, Issue 3, 2009, Pages 258-261

  Weiser, Thomas ^a   Just, Stefan ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Hyoscine butylbromide; N butyl scopolamine; Nicotinic receptor; SH SY5Y; Voltage clamp

Indexed keywords

ACETYLCHOLINE; BUSCAPINA; HEXAMETHONIUM; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE BUTYL BROMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; AUTONOMIC NERVE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INNERVATION; MEMBRANE CURRENT; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SPASMOLYSIS;

ACETYLCHOLINE; BUTYLSCOPOLAMMONIUM BROMIDE; CELL LINE, TUMOR; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTERIC NERVOUS SYSTEM; GANGLIONIC BLOCKERS; HEXAMETHONIUM; HUMANS; MEMBRANE POTENTIALS; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH; NEURONS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PARASYMPATHOLYTICS; RECEPTORS, NICOTINIC;

EID: 58249086335     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.12.004     Document Type: Article

References (19)

1. Ascher P., Large W.A., and Rang H.P. Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells. J. Physiol. 295 (1979) 139-170
2. Galligan J.J. Ligand-gated ion channels in the enteric nervous system. Neurogastroenterol. Mot. 14 (2002) 611-623
3. Gershon M.D., and Bursztajn S. Properties of the enteric nervous system: limitation of access of intravascular macromolecules to the myenteric plexus and muscularis externa. J. Comp. Neurol. 180 (1978) 467-488
4. Groot Kormelink P.J., and Luyten W.H. Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32. FEBS Lett. 400 (1997) 309-314
5. Lukas R.J., Norman S.A., and Lucero L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol. Cell. Neurosci. 4 (1993) 1-12
6. Müller-Lissner S., Tytgat G.N., Paulo L.G., Quigley E.M.M., Bubeck J., Peil H., and Schäfer E. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment. Pharmacol. Ther. 23 (2006) 1741-1748
7. Pomeroy A.R., and Rand M.J. Anticholinergic effects and passage through the intestinal wall of N-butylhyoscine bromide. J. Pharm. Pharmacol. 21 (1969) 180-187
8. Puchacz E., Buisson B., Bertrand D., and Lukas R.J. Functional expression of nicotinic acetylcholine receptors containing rat alpha 7 subunits in human SH-SY5Y neuroblastoma cells. FEBS Lett. 354 (1994) 155-159
9. Schäfer E., and Ewe K. Behandlung des Colon irritabile: Wirksamkeit und Vertraeglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile. Fortschr. Med. 108 (1990) 488-492
10. Smulders C.J., Zwart R., Bermudez I., van Kleef R.G., Groot-Kormelink P.J., and Vijverberg H.P. Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur. J. Pharmacol. 509 (2005) 97-108
11. Sokolova E., Matteoni C., and Nistri A. Desensitization of neuronal nicotinic receptors of human neuroblastoma SH-SY5Y cells during short or long exposure to nicotine. Br. J. Pharmacol. 146 (2005) 1087-1095
12. Toselli M., Perin P., and Taglietti V. Muscarine inhibits omega-conotoxin-sensitive calcium channels in a voltage- and time-dependent mode in the human neuroblastoma cell line SH-SY5Y. J. Neurophysiol. 74 (1995) 1730-1741
13. Tytgat G.N. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67 (2007) 1343-1357
14. Tytgat G.N. Hyoscine butylbromide-a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr. Med. Res. Opin. 24 (2008) 3159-3173
15. Wang F., Nelson M.E., Kuryatov A., Olale F., Cooper J., Keyser K., and Lindstrom J. Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells. J. Biol. Chem. 273 (1998) 28721-28732
16. Weiser T., Iizuka M., Nishimura S., Akiba I., Barsoumian E., Zhou M., Steinhäuser C., Brenner M., Palluk R., and Wienrich M. Characterization of the anticonvulsant and neuroprotectant BIIR 561 CL in vitro: effects on native and recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Naunyn Schmiedebergs Arch. Pharmacol. 362 (2000) 419-426
17. Wick H. Pharmacology of buscopan. Arch. Exp. Pathol. Pharmakol. 213 (1951) 485-500
18. Zhou X., Ren J., Brown E., Schneider D., Caraballo-Lopez Y., and Galligan J.J. Pharmacological properties of nicotinic acetylcholine receptors expressed by guinea pig small intestinal myenteric neurons. J. Pharmacol. Exp. Ther. 302 (2002) 889-897
19. Zwart R., and Vijverberg H.P. Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol. Pharmacol. 52 (1997) 886-895